Nyxol + Pilocarpine Drug Market

"Nyxol + Pilocarpine Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Nyxol + Pilocarpine for Presbyopia in the 7MM. A detailed picture of the Nyxol + Pilocarpine for Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Nyxol + Pilocarpine for Presbyopia. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Nyxol + Pilocarpine market forecast, analysis for Presbyopia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Presbyopia.

 

Nyxol + Pilocarpine Drug Summary

Nyxol is a preservative-free ophthalmic solution that contains 0.75% phentolamine (1% phentolamine mesylate), a nonselective alpha-adrenergic antagonist which inhibits the contraction of the smooth muscle of the iris. Nyxol is being developed under the 505(b) (2) pathway.

Its potential to improve near vision is based on its mechanism of reducing pupil diameter, which results in an increased depth of focus. Reducing pupil diameter to the 1.6–2.0 mm range (""pinhole effect"") leads to an improvement in near vision.

In various Phase II trials, Nyxol alone has reduced pupil diameter, improving visual acuity by one eye chart line for over 24 hours after an evening eye drop.

It is also being evaluated as part of adjunctive therapy, with a two-drug kit provided to patients, with Nyxol to be applied once daily in the evening and low-dose pilocarpine (0.4%) in the daytime, where Nyxol is responsible for iris dilator muscle inhibition and pilocarpine for iris sphincter muscle activation.

Ocuphire Pharma is developing it as a single drop as well as an adjunct therapy for the treatment of presbyopia. Recently, it completed a Phase II trial to assess the safety and efficacy of Nyxol with low dose pilocarpine eye drops in subjects.

The company plans to initiate the VEGA Phase III program for investigating Nyxol alone and Nyxol with low-dose pilocarpine (LDP) as an adjunctive treatment for the potential treatment of presbyopia.

 

Scope of the Nyxol + Pilocarpine Drug Market Report

The report provides insights into:

• A comprehensive product overview including the Nyxol + Pilocarpine description, mechanism of action, dosage and administration, research and development activities in Presbyopia.

• Elaborated details on Nyxol + Pilocarpine regulatory milestones and other development activities have been provided in this report.

• The report also highlights the Nyxol + Pilocarpine research and development activity in Presbyopia in detail across the United States, Europe and Japan.

• The report also covers the patents information with expiry timeline around Nyxol +Pilocarpine.

• The report contains forecasted sales of Nyxol + Pilocarpine for Presbyopia till 2032.

• Comprehensive coverage of the late-stage emerging therapies for Presbyopia.

• The report also features the SWOT analysis with analyst views for Nyxol + Pilocarpine in Presbyopia.

 

Nyxol + Pilocarpine Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Nyxol + Pilocarpine Analytical Perspective by DelveInsight

• In-depth Nyxol + Pilocarpine Market Assessment

This report provides a detailed market assessment of Nyxol + Pilocarpine in Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Nyxol + Pilocarpine Clinical Assessment

The report provides the clinical trials information of Nyxol + Pilocarpine in Presbyopia covering trial interventions, trial conditions, trial status, start and completion dates.

 

Nyxol + Pilocarpine Drug Market Report Highlights  

• In the coming years, the market scenario for Presbyopia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   

• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Nyxol + Pilocarpine dominance.

• Other emerging products for Presbyopia are expected to give tough market competition to Nyxol + Pilocarpine and launch of late-stage emerging therapies in the near future will significantly impact the market. 

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Nyxol + Pilocarpine in Presbyopia.

• Our in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nyxol + Pilocarpine in Presbyopia. 

 

Key Questions

• What is the product type, route of administration and mechanism of action of Nyxol + Pilocarpine?

• What is the clinical trial status of the study related to Nyxol + Pilocarpine in Presbyopia and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nyxol + Pilocarpine development?

• What are the key designations that have been granted to Nyxol + Pilocarpine for Presbyopia?

• What is the forecasted market scenario of Nyxol + Pilocarpine for Presbyopia?

• What are the forecasted sales of Nyxol + Pilocarpine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  

• What are the other emerging products available in Presbyopia and how are they giving competition to Nyxol + Pilocarpine for Presbyopia?

• Which are the late-stage emerging therapies under development for the treatment of Presbyopia?